Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07423546 · ClinicalTrials.gov registry record · Phase 1
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07423546 is a Phase 1 study that is actively recruiting participants, run by New York State Psychiatric Institute. The registered enrollment target is 12 participants.
The verdict
NCT07423546, a Phase 1 study, is actively recruiting participants, sponsored by New York State Psychiatric Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. \[18F\]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission. The overall objective of the current study is to measure Cobenfy's ability to engage its putative target (DA transmission/synthesis capacity in the striatum and midbrain as measured by \[18F\]DOPA Kicer (\[18F\]DOPA relative uptake rate)).
Interventions
- DRUG Xanomeline and trospium chloride (KarXT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07423546
The ClinicalTrials.gov registry entry for NCT07423546 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Xanomeline and trospium chloride (KarXT) is the first listed.
NCT07423546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07423546 about?
NCT07423546 is a clinical study titled "A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia". This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. \[18F\]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission. The overall ...
What is the current status of trial NCT07423546?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-07-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT07423546?
The interventions under investigation include: Xanomeline and trospium chloride (KarXT) (DRUG).
Who is sponsoring clinical trial NCT07423546?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.